Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH Annual Meeting

Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented from first-in-human studies of two investigational menin inhibitors, SNDX-5613 and KO-539,...

Descripción completa

Detalles Bibliográficos
Autores principales: DiNardo, Katherine W., LeBlanc, Thomas W., Chen, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983204/
https://www.ncbi.nlm.nih.gov/pubmed/36869366
http://dx.doi.org/10.1186/s13045-023-01411-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983204/
https://www.ncbi.nlm.nih.gov/pubmed/36869366
http://dx.doi.org/10.1186/s13045-023-01411-x

Ejemplares similares